Gender has a strong modulating effect on the risk of Alzheimer's disease conferred by the apolipoprotein E gene in the population of the Canary Islands, Spain;Fuerte modulación del sexo sobre el riesgo conferido por el gen de la apolipoproteína E para la enfermedad de Alzheimer en la población de las Islas Canarias, España

Revista de Neurologia

Volumn 38, Issue 7, 2004, Pages 615-618

  Deniz Naranjo M C ^a   Munoz Fernandez C ^a   Alemany Rodriguez M J ^a   Perez Vieitez M C ^a   Aladro Benito, Y ^a   Irurita Latasa, J ^b   Suarez Armas R ^a   Suarez Valentin M P ^a   Sánchez García, Florentino ^a,b  

^a HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

^b HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

Author keywords

Alzheimer disease; Canary Islands; Exonic ApoE polymorphisms; Promoter ApoE polymorphisms; Spain

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E4; ISOPROTEIN;

ADULT; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; DNA POLYMORPHISM; EXON; FEMALE; GENDER; GENETIC PREDISPOSITION; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK; SPAIN; AGED; ALLELE; ATLANTIC ISLANDS; GENE DOSAGE; GENE FREQUENCY; GENETICS; GENOTYPE; ONSET AGE; SEX DIFFERENCE;

AGE OF ONSET; AGED; ALLELES; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; ATLANTIC ISLANDS; EXONS; FEMALE; GENE DOSAGE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; PROMOTER REGIONS (GENETICS); PROTEIN ISOFORMS; RISK; SEX FACTORS; SPAIN;

EID: 2942700105     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3807.2003264     Document Type: Article

References (35)

1. Pericak-Vance MA, Bebout JL, Gaskell PC Jr, Yamaoka LH, Hung WY, Alberts MJ, et al. Linkage studies in familial Alzheimer disease: evidence for chromosome 19 linkage. Am J Hum Genet 1991; 48: 1034-50.
2. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, et al. Apolipoprotein E: high-avidity binding to betaamyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 1993; 90: 1977-81.
3. Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 1993; 43: 1467-72.
4. Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell Jr, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer. Nat Genet 1994; 7: 180-4.
5. Roses AD, Strittmatter WJ, Pericak-Vance MA, Corder EH, Saunders AM, Schmechel DE. Clinical application of apolipoprotein E genotyping to Alzheimer's disease. Lancet 1994; 343: 1564-5.
6. Frisoni GB, Manfredi M, Geroldi C, Binetti G, Zanetti O, Bianchetti A, et al. The prevalence of apoE-epsilon4 in Alzheimer's disease is age dependent. J Neurol Neurosurg Psychiatry 1998; 65: 103-6.
7. Kim HC, Kim DK, Choi IJ, Kang KH, Yi SD, Park J, et al. Relation of apolipoprotein E polymorphism to clinically diagnosed Alzheimer's disease in the Korean population. Psychiatry Clin Neurosci 2001; 55: 115-20.
8. Goldstein FC, Ashley AV, Gearing M, Hanfelt J, Penix L, Freedman LJ, et al. Apolipoprotein E and age at onset of Alzheimer's disease in African American patients. Neurology 2001; 57: 1923-5.
9. Dal Forno G, Carson KA, Brookmeyer R, Troncoso J, Kawas CH, Brandt J. ApoE genotype and survival in men and women with Alzheimer's disease. Neurology 2002; 58: 1045-50.
10. Saunders AM. Apolipoprotein E and Alzheimer disease: an update on genetic and functional analyses. J Neuropathol Exp Neurol 2000; 59: 751-8.
11. Bullido MJ, Artiga MJ, Recuero M, Sastre I, García MA, Aldudo J, et al. A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia. Nat Genet 1998; 18: 69-71.
12. Sambrook J, Fritsch E, Maniatis T. Molecular cloning. A laboratory manual. 2 ed. New York: Cold Spring Harbor Laboratory Press; 1989. p. E3-4.
13. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hha I. J Lipid Res 1990; 31: 545-8.
14. Artiga MJ, Bullido MJ, Frank A, Sastre I, Recuero M, García MA, et al. Risk for Alzheimer's disease correlates with transcriptional activity of the APOE gene. Hum Mol Genet 1998; 7: 1887-92.
15. Artiga MJ, Bullido MJ, Sastre I, Recuero M, García MA, Aldudo J, et al. Allelic polymorphisms in the transcriptional regulatory region of apolipoprotein E gene. FEBS Lett 1998; 421: 105-8.
16. Alberca R, Montes-Latorre E, Gil-Néciga E, Mir-Rivera P, Lozano-San Martín P. Enfermedad de Alzheimer y mujer. Rev Neurol 2002; 35: 571-9.
17. Adroer R, Santacruz P, Blesa R, López-Pousa S, Ascaso C, Oliva R. Apolipoprotein ε4 allele frequeny in Spanish Alzheimer and control cases. Neurosci Lett 1995; 189: 182-6.
18. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997; 278: 1349-56.
19. López OL, López-Pousa S, Kamboh MI, Adroer R, Oliva R, Lozano-Gallego M, et al. Apolipoprotein E polymorphism in Alzheimer's disease: a comparative study of two research populations from Spain and the United States. Eur Neurol 1998; 39: 229-33.
20. Quiroga P, Calvo C, Albala C, Urquidi J, Santos JL, Pérez H, et al. Apolipoprotein E polymorphism in elderly Chilean people with Alzheimer's disease. Neuroepidemiology 1999; 18: 48-52.
21. Graff-Radford NR, Green RC, Go RC, Hutton ML, Edeki T, Bachman D, et al. Association between apolipoprotein E genotype and Alzheimer disease in African American subjects. Arch Neurol 2002; 59: 594-600.
22. Benedetti MD, Salviati A, Filipponi S, Manfredi M, De Togni L, Gómez-Lira M, et al. Prevalence of dementia and apolipoprotein E genotype distribution in the elderly of Buttapietra, Verona province, Italy. Neuroepidemiology 2002; 21: 74-80.
23. Aerssens J, Raeymaekers P, Lilienfeld S, Geerts H, Konings F, Parys W. APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease. Dement Geriatr Cogn Disord 2001; 12: 69-77.
24. Payami H, Zareparsi S, Montee KR, Sexton GJ, Kaye JA, Bird TD, et al. Gender difference in apolipoprotein E-associated risk for familial Alzheimer disease: a possible clue to the higher incidence of Alzheimer disease in women. Am J Hum Genet 1996; 58: 803-11.
25. Molero AE, Pino-Raméez G, Maestre GE. Modulation by age and gender of risk for Alzheimer's disease and vascular dementia associated with the apolipoprotein E-varepsilon4 allele in Latin Americans: findings from the Maracaibo Aging Study. Neurosci Lett 2001; 307: 5-8.
26. Bretsky PM, Buckwalter JG, Seeman TE, Miller CA, Poirier J, Schellenberg GD, et al. Evidence for an interaction between apolipoprotein E genotype, gender, and Alzheimer disease. Alzheimer Dis Assoc Disord 1999; 13: 216-21.
27. Ghebremedhin E, Schultz C, Thal DR, Rub U, Ohm TG, Braak E, et al. Gender and age modify the association between APOE and AD-related neuropathology. Neurology 2001; 56: 1696-701.
28. Bretsky PM, Buckwalter JG, Seeman TE, Miller CA, Poirier J, Schellenberg GD, et al. Evidence for an interaction between apolipoprotein E genotype, gender, and Alzheimer disease. Alzheimer Dis Assoc Disord 1999; 13: 216-21.
29. Combarros O, Leno C, Oterino A, Berciano J, Fernández-Luna JL, Fernández-Viadero C, et al. Gender effect on apolipoprotein E epsilon4 allele-associated risk for sporadic Alzheimer's disease. Acta Neurol Scand 1998; 97: 68-71.
30. Town T, París D, Fallin D, Duara R, Barker W, Gold M, et al. The -491 A/T apolipoprotein E promoter polymorphism association with Alzheimer's disease: independent risk and linkage disequilibrium with the known APOE polymorphism. Neurosci Lett 1998; 252: 95-8.
31. Helisalmi S, Hiltunen M, Valonene P, Mannermaa A, Koivisto AM, Lehtovirta M, et al. Promoter polymorphism (-491 A/T) in the APOE gene of Finnish Alzheimer's disease patients and control individuals. J Neurol 1999; 246: 821-4.
32. Halimi G, Duplan L, Bideau C, Iniesta D, Berthézéne P, Oddoze C, et al. Association of APOE promoter but not A2M polymorphisms with risk of developing Alzheimer's disease. Neuroreport 2000; 11: 3599-601.
33. Toji H, Maruyama H, Sasaki K, Nakamura S, Kawakami H. Apolipoprotein E promoter polymorphism and sporadic Alzheimer's disease in a Japanese population. Neurosci Lett 1999; 259: 56-8.
34. Thome J, Gewirtz JC, Sakai N, Zachariou V, Retz-Junginger P, Retz W, et al. Polymorphism of the human apolipoprotein E promoter and bleomycin hydrolase gene: risk factors for Alzheimer's dementia? Neurosci Lett 1999; 274: 37-40.
35. Chen L, Baun L, Ng HK, Chan LY, Sastre I, Artiga MJ, et al. Apolipoprotein E promoter and alpha 2-macroglobulin polymorphisms are not genetically associated with Chinese late onset Alzheimer's disease. Neurosci Lett 1999; 269: 173-7.